AR and neoplasm: Although androgen-deprivation therapies and/or the administration of first-generation competitive AR inhibitors prevent further tumor growth for a while, most patients develop resistance to the treatment and subsequently progress to castration-resistant prostate cancer (CRPC) (Fig. 1a) [2].